KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Amgen Inc AMGN
News
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Amgen Down Nearly 7%, On Pace For Largest Percent Decrease Since March 2020 — Data Talk
Beneath the surface, the next stock-market leaders are getting ready to break out, says Morgan Stanley
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Why the Dow is being dragged down by a Swiss company's bad news
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
FTC Challenges Amgen's Patent Play in Enbrel Antitrust Case
Moderna's cancer-vaccine breakthrough drives broad biopharma stock rally
Amgen Lifts Outlook on Strong 2Q Drug Sales, to End Early Development of Obesity Treatment
AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND
AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS
European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked
Kissei Revises Package Insert in Japan for Amgen's Tavneos
Amgen Names Thomas Dittrich as Finance Chief
United States